We develop novel biotechnologies for clinical translation based on the
understanding of underlying biological mechanisms and disease pathology.

About Us

Welcome to the Center for Engineered Therapeutics – Clinical Translation of Discoveries from Engineering in Medicine. Our mission is to develop novel biotechnologies to overcome currently incurable diseases and injuries, with the end goal of achieving life extension and overcome ageing. We study biology to define important medical questions and use principles of engineering in medicine to realize rigorous therapeutics and enhance the efficacy and safety of engineered therapeutics in the clinic.

Our center is located within the rich ecosystem of the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and the Harvard-MIT Division of HST. We have an interdisciplinary research environment where engineers, biologists, chemists, physicists, pharmacists, material scientists, and clinicians work together to solve biological challenges in holistic and creative approaches. We love exciting and hard problems that will have an impact on patient's lives.

Featured Publications

Computationally designed antibody-drug conjugates self-assembled via affinity ligands Transcellular transfer of nanomedicine A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer

Reporter nanoparticle that monitors its anticancer efficacy in real time Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity

Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anticancer Efficacy